CR20110033A - Cristal de derivados de espirocetal, y procedimiento para la preparación de derivados de espirocetal - Google Patents

Cristal de derivados de espirocetal, y procedimiento para la preparación de derivados de espirocetal

Info

Publication number
CR20110033A
CR20110033A CR20110033A CR20110033A CR20110033A CR 20110033 A CR20110033 A CR 20110033A CR 20110033 A CR20110033 A CR 20110033A CR 20110033 A CR20110033 A CR 20110033A CR 20110033 A CR20110033 A CR 20110033A
Authority
CR
Costa Rica
Prior art keywords
spirocetal
derivatives
crystal
procedure
preparation
Prior art date
Application number
CR20110033A
Other languages
English (en)
Inventor
Masatoshi Murakata
Takuma Ikeda
Nobuaki Kimura
Akira Kawase
Masahiro Nagase
Keisuke Yamamoto
Takata Noriyuki
Yoshizaki Shinichi
Original Assignee
Chugai Pharmaceutical Co Ltd
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41434188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110033(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Univ Texas filed Critical Chugai Pharmaceutical Co Ltd
Publication of CR20110033A publication Critical patent/CR20110033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención provee un procedimiento para preparar un derivado de espirocetal, por medio de un intermediario representado por la fórmula VI, en donde los grupos y números variables son como se definen en la especificación, y el cual puede producirse de derivados de dihalobenceno en una reacción en un recipiente.
CR20110033A 2008-06-20 2011-01-19 Cristal de derivados de espirocetal, y procedimiento para la preparación de derivados de espirocetal CR20110033A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008162073 2008-06-20

Publications (1)

Publication Number Publication Date
CR20110033A true CR20110033A (es) 2011-02-16

Family

ID=41434188

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110033A CR20110033A (es) 2008-06-20 2011-01-19 Cristal de derivados de espirocetal, y procedimiento para la preparación de derivados de espirocetal

Country Status (24)

Country Link
US (2) US8569520B2 (es)
EP (3) EP3170834B8 (es)
JP (2) JP4823385B2 (es)
KR (1) KR101856784B1 (es)
CN (1) CN102046645B (es)
AR (1) AR072211A1 (es)
AU (1) AU2009261129A1 (es)
CA (1) CA2727923A1 (es)
CL (1) CL2010001485A1 (es)
CO (1) CO6351798A2 (es)
CR (1) CR20110033A (es)
EC (1) ECSP11010773A (es)
ES (1) ES2907611T3 (es)
IL (1) IL210098A0 (es)
MA (1) MA32530B1 (es)
MX (1) MX2010014023A (es)
NZ (1) NZ589961A (es)
PE (1) PE20110115A1 (es)
PL (1) PL3170834T3 (es)
RU (1) RU2011101972A (es)
SG (1) SG193795A1 (es)
TW (1) TW201011043A (es)
WO (1) WO2009154276A1 (es)
ZA (1) ZA201100016B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5711669B2 (ja) * 2009-12-18 2015-05-07 中外製薬株式会社 スピロケタール誘導体の製造方法
WO2012115249A1 (ja) * 2011-02-25 2012-08-30 中外製薬株式会社 スピロケタール誘導体の結晶
CN104039785A (zh) * 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
AU2014370847B2 (en) 2013-12-27 2020-02-20 Chugai Seiyaku Kabushiki Kaisha Solid preparations containing tofogliflozin and process of producing the same
CN106188190B (zh) * 2016-07-28 2020-08-25 迪嘉药业集团有限公司 一种托格列净一水合物的制备方法
BR112019005930A2 (pt) 2016-10-19 2019-06-11 Boehringer Ingelheim Int combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
CN108640958B (zh) * 2017-05-05 2021-03-30 镇江圣安医药有限公司 异苯并呋喃衍生物、其药物组合物和制剂以及用途
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK3873600T5 (da) 2018-10-29 2024-03-18 Boehringer Ingelheim Int Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
PT98344B (pt) 1991-07-17 1999-04-30 Lneti Lab Nac De Eng Tec Ind D Processo para a obtencao de espirocetais labdanicos do tipo ambar cinzento
GB9426103D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
JP2000044534A (ja) 1998-07-28 2000-02-15 Mitsui Chemicals Inc Ｎ保護基アミノ酸の製造法
WO2001057046A1 (en) 2000-02-02 2001-08-09 Banyu Pharmaceutical Co., Ltd. Method of converting functional group through halogen-metal exchange reaction
JP3849024B2 (ja) 2003-03-26 2006-11-22 国立大学法人 東京大学 有機亜鉛錯体およびその製造方法
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
CN101389632B (zh) 2005-12-23 2013-02-06 生态生物有限公司 螺缩酮
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes

Also Published As

Publication number Publication date
CN102046645A (zh) 2011-05-04
IL210098A0 (en) 2011-02-28
ZA201100016B (en) 2012-03-28
MX2010014023A (es) 2011-02-15
PE20110115A1 (es) 2011-02-14
ECSP11010773A (es) 2011-02-28
KR101856784B1 (ko) 2018-05-10
ES2907611T3 (es) 2022-04-25
HK1154589A1 (en) 2012-04-27
CO6351798A2 (es) 2011-12-20
TW201011043A (en) 2010-03-16
EP3170834B8 (en) 2022-03-23
JP5485237B2 (ja) 2014-05-07
CL2010001485A1 (es) 2011-09-16
AU2009261129A1 (en) 2009-12-23
EP2308886A1 (en) 2011-04-13
AR072211A1 (es) 2010-08-11
PL3170834T3 (pl) 2022-05-02
SG193795A1 (en) 2013-10-30
US20110306778A1 (en) 2011-12-15
EP4036100A1 (en) 2022-08-03
JP4823385B2 (ja) 2011-11-24
RU2011101972A (ru) 2012-07-27
KR20110020909A (ko) 2011-03-03
JP2012001554A (ja) 2012-01-05
US20140024817A1 (en) 2014-01-23
CN102046645B (zh) 2015-04-01
CA2727923A1 (en) 2009-12-23
EP3170834A1 (en) 2017-05-24
US9163051B2 (en) 2015-10-20
EP2308886B1 (en) 2016-12-07
NZ589961A (en) 2012-12-21
JPWO2009154276A1 (ja) 2011-12-01
US8569520B2 (en) 2013-10-29
WO2009154276A1 (ja) 2009-12-23
EP3170834B1 (en) 2022-02-09
MA32530B1 (fr) 2011-08-01
EP2308886A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
CR20110033A (es) Cristal de derivados de espirocetal, y procedimiento para la preparación de derivados de espirocetal
ECSP12011909A (es) Derivados de glicósido y usos de los mismos
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
CR11751A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta3
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP11010804A (es) Compuestos orgánicos
UY33256A (es) Procedimiento de sintesis de derivados de cetobenzofurano
ECSP11011288A (es) Derivados de indol como antagonistas del receptor crth2
DOP2011000198A (es) Compuestos y metodos de uso
CU20130101A7 (es) Derivados de 1,4-oxazin-3-il-piridin-2-il-acetamida, activos como inhibidores bace-1 o bace-2
ECSP12011830A (es) Nuevos compuestos.
AR061727A1 (es) Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
EA201500234A1 (ru) Способ получения бензоксазинонов
ECSP11011218A (es) Herbicidas derivados de ciclopentanodiona.
ECSP11010816A (es) Nuevos Compuestos
EA201591530A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
DOP2016000211A (es) Pirazinas moduladoras de gpr6
UY32524A (es) Moduladores de sip y método para producirlos y usarlos
BR112012020855A2 (pt) Método para produzir um conjugado de biomolécula
EA201200820A1 (ru) Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов
CO6460762A2 (es) 5-alquinil-piridinas
EA201001362A1 (ru) Хинолины в качестве ингибиторов фарнезилпирофосфатсинтазы
ECSP17058071A (es) Derivados de tetrahidropiranil benzamida
WO2010029457A3 (en) An improved process for preparing losartan potassium

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)